CN105816473B - A kind of flavonoid glycoside composition and its preparation and preparation method - Google Patents
A kind of flavonoid glycoside composition and its preparation and preparation method Download PDFInfo
- Publication number
- CN105816473B CN105816473B CN201510392152.5A CN201510392152A CN105816473B CN 105816473 B CN105816473 B CN 105816473B CN 201510392152 A CN201510392152 A CN 201510392152A CN 105816473 B CN105816473 B CN 105816473B
- Authority
- CN
- China
- Prior art keywords
- composition
- glycosides
- flavonoid glycoside
- glycoside composition
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 131
- 229930182486 flavonoid glycoside Natural products 0.000 title claims abstract description 64
- 150000007955 flavonoid glycosides Chemical class 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims description 25
- -1 Quercetin glycosides Chemical class 0.000 claims abstract description 86
- 229930182470 glycoside Natural products 0.000 claims abstract description 75
- REFJWTPEDVJJIY-UHFFFAOYSA-N quercetin Natural products C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 31
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 30
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 26
- KJXSIXMJHKAJOD-LSDHHAIUSA-N Ampelopsin Natural products C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 claims abstract description 25
- 235000005875 quercetin Nutrition 0.000 claims abstract description 24
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 23
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960001285 quercetin Drugs 0.000 claims abstract description 23
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 claims abstract description 21
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000007625 naringenin Nutrition 0.000 claims abstract description 21
- 229940117954 naringenin Drugs 0.000 claims abstract description 21
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 claims abstract description 20
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000011797 eriodictyol Nutrition 0.000 claims abstract description 20
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000013422 Kaempferia rotunda Nutrition 0.000 claims abstract description 16
- 235000010208 anthocyanin Nutrition 0.000 claims abstract description 16
- 229930002877 anthocyanin Natural products 0.000 claims abstract description 16
- 239000004410 anthocyanin Substances 0.000 claims abstract description 16
- 150000004636 anthocyanins Chemical class 0.000 claims abstract description 16
- 229930182487 phenolic glycoside Natural products 0.000 claims abstract description 16
- 150000007950 phenolic glycosides Chemical class 0.000 claims abstract description 16
- 244000062250 Kaempferia rotunda Species 0.000 claims abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000007788 liquid Substances 0.000 claims description 17
- 244000132436 Myrica rubra Species 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 238000001556 precipitation Methods 0.000 claims description 11
- 229910002027 silica gel Inorganic materials 0.000 claims description 11
- 239000000741 silica gel Substances 0.000 claims description 11
- 229960001866 silicon dioxide Drugs 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 239000003826 tablet Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000003480 eluent Substances 0.000 claims description 6
- ATYGMDZIBQHJFX-UHFFFAOYSA-N imidazolidine;urea Chemical compound NC(N)=O.C1CNCN1 ATYGMDZIBQHJFX-UHFFFAOYSA-N 0.000 claims description 6
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 229920002907 Guar gum Polymers 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000665 guar gum Substances 0.000 claims description 5
- 229960002154 guar gum Drugs 0.000 claims description 5
- 235000010417 guar gum Nutrition 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 244000269722 Thea sinensis Species 0.000 claims 4
- 229930003944 flavone Natural products 0.000 abstract description 22
- 235000011949 flavones Nutrition 0.000 abstract description 22
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 20
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 17
- 150000002338 glycosides Chemical class 0.000 abstract description 11
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 150000001720 carbohydrates Chemical class 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 34
- 241001122767 Theaceae Species 0.000 description 19
- 235000019441 ethanol Nutrition 0.000 description 15
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 241000395033 Kaempferia Species 0.000 description 12
- 241000700159 Rattus Species 0.000 description 8
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 7
- 150000002212 flavone derivatives Chemical class 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 235000008777 kaempferol Nutrition 0.000 description 7
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 7
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229930003935 flavonoid Natural products 0.000 description 6
- 235000017173 flavonoids Nutrition 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 229940126670 AB-836 Drugs 0.000 description 5
- 235000007652 Arbutus Nutrition 0.000 description 5
- 240000008327 Arbutus unedo Species 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 229930014669 anthocyanidin Natural products 0.000 description 4
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 4
- 235000008758 anthocyanidins Nutrition 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002893 slag Substances 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010018473 Glycosuria Diseases 0.000 description 2
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 239000003082 abrasive agent Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 2
- 235000007743 myricetin Nutrition 0.000 description 2
- 229940116852 myricetin Drugs 0.000 description 2
- 229940043348 myristyl alcohol Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000002926 oxygen Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940022860 xylitan Drugs 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical class C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000027849 smooth muscle hyperplasia Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009441 vascular protection Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of flavonoid glycoside composition, said composition is mainly prepared by Quercetin glycosides, kaempferia galamga phenolic glycoside, dihydromyricetin glycosides, anthocyanin, naringenin glycosides and eriodictyol glycosides by certain part by weight ratio is processed；Said composition to diabetes and its complication to having the effect of fine.Flavone compound and any rationally carbohydrate combine to form flavonoid glycoside compound with glycosidic bond, utilize the structure into glycosides, on the premise of aglycon is not influenceed as the therapeutic effect of active ingredient, improve the stability of flavone compound, and glycoside is readily soluble, it is very fast in people's body absorption, it can preferably play the therapeutic action of aglycon.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, more particularly to a kind of flavonoid glycoside composition and its preparation and preparation method.
Background technology
Diabetes are one group of lifelong participation metabolic diseases as caused by multi-pathogenesis characterized by chronic hyperglycemia.Diabetes
Itself not necessarily damage, but long-term blood glucose increases, and big blood vessel, capilary are damaged and jeopardize the heart, brain, kidney, peripheral nerve, eye
Eyeball, foot etc., are counted according to the World Health Organization, and diabetic complication is up to kind more than 100, are to be currently known the most one kind of complication
Disease.Caused by Diabetes Death person has more than half to be cardiovascular and cerebrovascular, caused by 10% is nephropathy, because of glycosuria in patients with amputation
Disease initiation is 10~20 times of other reasonses.Therefore it is that vital society is asked to treat and prevent diabetes and its complication
Topic.
With the understanding to diabetes and its complication pathogenesis, medicine and the guide of preventing and treating diabetes and its complication
Compound is also found and studied in succession, and wherein flavone compound is as a kind of natural production with bioactivity in nature
Thing, also gradually cause the attention of the world of medicine.The many flavone compounds of discovered in recent years have necessarily to diabetes and its complication
Preventive and therapeutic action, the especially compound such as Quercetin and dihydromyricetin, such as disclosed in Chinese patent 101674821
" with Quercetin, myricetin and chlorogenic acid treatment diabetes and metabolic disease composition ", can be used for treat patient sugar
Urine disease and metabolic disease and mitigation obese patient's body weight；Disclose that " Quercetin is to sugar in Chinese patent application 104000813A
Urinate the preventive and therapeutic effect of characteristic of disease cataract ".But the problem of presently, there are is, Flavonoid substances are easily oxidized, can not be for a long time normal
Temperature is lower to be stored, and has had a strong impact on its druggability and clinical popularization and application.In addition, the flavone compound or list of single kind
The total flavonoid composition treatment diabetes single effect of one plant, curative effect is not good enough.
The content of the invention
In order to solve the above-mentioned technical problem, the present invention provides a kind of property stabilization, and diabetes and complications Treatment are imitated
Fruit is obvious, and the flavonoid glycoside composition of Small side effects.
Concrete technical scheme of the present invention is as follows：
The present invention provides a kind of flavonoid glycoside composition, and said composition is mainly by the processed preparation of raw material of following parts by weight
Form：
Quercetin glycosides 0.01-20 kaempferia galamga phenolic glycoside 0.01-30 dihydromyricetin glycosides 0.01-20
Anthocyanin 0.01-20 naringenin glycosides 0.01-20 eriodictyol glycosides 0.01-20.
Flavone compound and effective glycogen are combined to form flavonoid glycoside compound by the present invention with glycosidic bond, using into glycosides
Structure, under the premise of aglycon is not influenceed as the therapeutic effect of active ingredient, improve the stability of flavone compound, and
Glycoside is readily soluble, very fast in people's body absorption, can preferably play the activity of aglycon.Flavonoid glycoside combination provided by the present invention
Diabetes and its complication are had unexpected good curative effect, far superior to single component by thing, each component synergy.Separately
Outside, the flavonoid glycoside composition for the treatment of diabetes and its complication provided by the present invention is nontoxic to human body, green safe.
Further preferred, preparing the raw materials used parts by weight of the composition is：
Quercetin glycosides 1-20 kaempferia galamga phenolic glycoside 20-26 dihydromyricetin glycosides 0.5-20
Anthocyanin 14-20 naringenin glycosides 2-20 eriodictyol glycosides 15-20.
Still more preferably, preparing the raw materials used parts by weight of the composition is：
The dihydromyricetin glycosides 20 of 1 kaempferia galamga phenolic glycoside of Quercetin glycosides 25
The eriodictyol glycosides 20 of 14 naringenin glycosides of anthocyanin 20.
In order to take and easy to carry, solid pharmaceutical preparation is made in flavonoid glycoside composition and auxiliary material of the present invention, the solid
Preparation includes tablet, capsule, powder or pill, and the ratio of weight and number of the composition and auxiliary material is 1:1.5-3.
Further preferably, tablet made of flavonoid glycoside composition and auxiliary material, the auxiliary material are included melon by the present invention
That glue, imidazolidine urea and white bole；The ratio of weight and number of the guar gum, imidazolidine urea and white bole is 8-10:1:10-12.
The guar gum and imidazolidine urea added in tablet provided by the present invention can shorten the disintegration time limited of tablet, beneficial to master
Want the dissolution of active component；White bole can promote the cohesive force between composition, without adding remaining adhesive, can improve into
Type；Tablet provided by the present invention has property stable, and disintegration is good, the beneficial effect such as evident in efficacy.
It is preferred that flavonoid glycoside composition of the present invention, is 1 by weight part ratio:1 red bayberry and the mixture of vine tea are
Made from raw material.Preparation method comprises the following steps：
1) take vine tea and stoning red bayberry to clean, mix, obtain mixture, it is standby；
2) mixture obtained by step 1) is added in the solvent of 4-6 times of gross weight and extracted, filtered, remove residue, concentrated,
By 1:8-8:1 ratio adds the mixture of alcohol and water, filters off except precipitation, supernatant cross silicagel column, using the solvent to wash
De- liquid is eluted, and is collected efflux 10-60min liquid, concentration, is volatilized, obtain flavonoid glycoside composition.
Further optimize preparation method, the solvent in the flavonoid glycoside preparation method is 70%-95% ethanol, the side
Method comprises the following steps：
1) take vine tea and stoning red bayberry to clean, mix, obtain mixture, it is standby；
2) mixture obtained by step 1) is added in the 70%-95% ethanol of 4-6 times of gross weight and extracted, filtered, removed
Residue, concentration, by 1:8 ratio adds the mixture of alcohol and water, filters off except precipitation, supernatant crosses silicagel column, with 95% second
Alcohol is that eluent is eluted, and collects efflux 10-30min liquid, concentration, volatilizes, obtain flavonoid glycoside composition.
Or the solvent in the flavonoid glycoside preparation method is pure water, methods described comprises the following steps：
1) take vine tea and stoning red bayberry to clean, mix, obtain mixture, it is standby；
2) mixture obtained by step 1) is added in the pure water of 4-6 times of gross weight and extracted, filtered, remove residue, concentrated,
By 8:1 ratio adds the mixture of alcohol and water, filters off except precipitation, supernatant cross silicagel column, is carried out by eluent of pure water
Elution, efflux 10-60min liquid is collected, concentration, volatilizes, obtains flavonoid glycoside composition.
On the other hand, the present invention also provides the flavonoid glycoside composition and prepared for treating diabetes and its complication
Medicine in application.
The novelty of the present invention is flavone compound and any rationally carbohydrate combining to form flavonoid glycoside with glycosidic bond
Class compound, using the structure into glycosides, on the premise of aglycon is not influenceed as the therapeutic effect of active ingredient, improve flavonoids
The stability of compound, and glycoside is readily soluble, it is very fast in people's body absorption, it can preferably play the therapeutic action of aglycon.Utilize
The combination of different flavonoid glycoside compounds, each component synergy, collaboration improve storage stability and anti-diabetic and its concurrent
The bioactivity of disease, there is unexpected good curative effect, far superior to single component to diabetes and its complication.In addition, this
It is nontoxic to human body that invention provides flavonoid glycoside composition, green safe, is a kind of safe efficient, stably anti-glycosuria
Disease and its complication product.
Bulk drug of the present invention is described as follows：
Quercetin：Also known as quercetin, Quercetin, Meletin Sophretin；Molecular formula：C15H10O7, yellow needles knot
Crystalline substance, belong to flavone compound, be present in the flower, leaf, fruit of many plants.Quercetin glycosides of the present invention is Quercetin with appointing
Anticipate the glycosides that reasonable glucide is combined to form with glycosidic bond.
Kaempferol：Also known as Kaempferol, Kaempferol, kaempferol Kaempferol, Kaempferol；Molecule
Formula：C15H10O6, yellow fine powder, belong to flavone compound, be present in the flower, leaf, fruit of many plants.Institute of the present invention
Kaempferia galamga phenolic glycoside is stated as Kaempferol and any glycosides that rationally glucide is combined to form with glycosidic bond.
Dihydromyricetin：Also known as ampeloptin, (2R, 3R) -3,5,7- trihydroxies -2- (3,4,5- trihydroxies phenyl) benzo two
Hydrogen pyrans -4- ketone, Dihydromyricetin；Molecular formula：C15H12O8, white, needle-shaped crystals, belong to flavone compound, source
For：The extract of vitis spp vine tea.Dihydromyricetin glycosides of the present invention is dihydromyricetin and any rationally carbohydrate thing
The glycosides that matter is combined to form with glycosidic bond.
Anthocyanidin：Also known as anthocyanidin (Anthocyanidin), molecular formula：C15H11O6, also known as anthocyanidin, it is nature
One kind is widely present in the water-soluble natural pigment in plant, belongs to flavonoids.It is combined with glucide with glycosidic bond
It is anthocyanin afterwards, is reddened etc. with colored color, leaf relevant, be a kind of natural antioxidant.
Naringenin：Naringenin is the glucoside member of naringin, also known as 4', 5,7- trihydroxyflavones, naringenin, Naringenin,
naringetol；Molecular formula：C15H12O5, white, needle-shaped crystals, fine powder, belong to flavanone kind composition.The present invention
The naringenin glycosides is naringenin and any glycosides that rationally glucide is combined to form with glycosidic bond.
Eriodictyol：Also known as eriodictyol, Eriodictyol, molecular formula：C15H12O6, light yellow crystalline powder, flavonoids
Compound, there is stronger antioxidant effect.Eriodictyol glycosides of the present invention is eriodictyol and any rationally glucide with sugar
The glycosides that glycosidic bond combines to form.
Brief description of the drawings
Fig. 1 is flavones glycoside composition, myricetin, vine tea flavone to Spontaneous Diabetic mouse blood vessel, cardiac muscle, kidney effect ratio
Compared with figure.
Embodiment
Embodiment 1
A kind of flavonoid glycoside composition, said composition processed are prepared by the raw material of following parts by weight：
The dihydromyricetin glycosides 12 of 0.01 kaempferia galamga phenolic glycoside of Quercetin glycosides 0.01
The eriodictyol glycosides 20 of 15 naringenin glycosides of anthocyanin 0.01.
Embodiment 2
A kind of flavonoid glycoside composition, said composition processed are prepared by the raw material of following parts by weight：
The dihydromyricetin glycosides 0.01 of 1 kaempferia galamga phenolic glycoside of Quercetin glycosides 5
The eriodictyol glycosides 0.01 of 20 naringenin glycosides of anthocyanin 20.
Embodiment 3
A kind of flavonoid glycoside composition, said composition processed are prepared by the raw material of following parts by weight：
The dihydromyricetin glycosides 20 of 20 kaempferia galamga phenolic glycoside of Quercetin glycosides 30
The eriodictyol glycosides 3 of 0.01 naringenin glycosides of anthocyanin 4.
Embodiment 4
A kind of flavonoid glycoside composition, said composition processed are prepared by the raw material of following parts by weight：
The dihydromyricetin glycosides 20 of 1 kaempferia galamga phenolic glycoside of Quercetin glycosides 25
The eriodictyol glycosides 20 of 14 naringenin glycosides of anthocyanin 20.
Preparation method：
1) weight vine tea and the stoning red bayberry such as take to clean, mix, obtain mixture, it is standby；
2) the new arbutus and vine tea described in step 1) are soaked in 95% ethanol of 4 times of gross weight and extracted, filtered,
Remove residue, concentration, by 1:8 ratio adds the mixture of alcohol and water, filters off except precipitation, supernatant cross silicagel column, with
95% ethanol is that eluent is eluted, and collects efflux 10min liquid, concentration, volatilizes, obtain flavonoid glycoside composition.
Embodiment 5
A kind of flavonoid glycoside composition, said composition processed are prepared by the raw material of following parts by weight：
The dihydromyricetin glycosides 20 of 18 kaempferia galamga phenolic glycoside of Quercetin glycosides 26
The eriodictyol glycosides 20 of 14 naringenin glycosides of anthocyanin 2.
Preparation method：
1) weight vine tea and the stoning red bayberry such as take to clean, mix, obtain mixture, it is standby；
2) the new arbutus and vine tea described in step 1) are soaked in 70% ethanol of 6 times of gross weight and extracted, filtered,
Remove residue, concentration, by 1:8 ratio adds the mixture of alcohol and water, filters off except precipitation, supernatant cross silicagel column, with
95% ethanol is that eluent is eluted, and collects efflux 30min liquid, concentration, volatilizes, obtain flavonoid glycoside composition.
Embodiment 6
A kind of flavonoid glycoside composition, said composition processed are prepared by the raw material of following parts by weight：
The dihydromyricetin glycosides 0.5 of 20 kaempferia galamga phenolic glycoside of Quercetin glycosides 24.5
The eriodictyol glycosides 15 of 20 naringenin glycosides of anthocyanin 20.
Preparation method：
1) weight vine tea and the stoning red bayberry such as take to clean, mix, obtain mixture, it is standby；；
2) the new arbutus and vine tea described in step 1) are soaked in the pure water of 6 times of gross weight and extracted, filtered, removed residual
Slag, concentration, by 8:1 ratio adds the mixture of alcohol and water, filters off except precipitation, supernatant cross silicagel column, using pure water to wash
De- liquid is eluted, and is collected efflux 10min liquid, concentration, is volatilized, obtain flavonoid glycoside composition.
Embodiment 7
A kind of flavonoid glycoside composition, said composition processed are prepared by the raw material of following parts by weight：
The dihydromyricetin glycosides 0.5 of 15 kaempferia galamga phenolic glycoside of Quercetin glycosides 24.5
The eriodictyol glycosides 20 of 20 naringenin glycosides of anthocyanin 20.
Preparation method：
1) weight vine tea and the stoning red bayberry such as take to clean, mix, obtain mixture, it is standby；
2) the new arbutus and vine tea described in step 1) are soaked in the pure water of 4 times of gross weight and extracted, filtered, removed residual
Slag, concentration, by 7:1 ratio adds the mixture of alcohol and water, filters off except precipitation, supernatant cross silicagel column, using pure water to wash
De- liquid is eluted, and is collected efflux 25min liquid, concentration, is volatilized, obtain flavonoid glycoside composition.
Embodiment 8
A kind of flavonoid glycoside composition, said composition processed are prepared by the raw material of following parts by weight：
The dihydromyricetin glycosides 8 of 6 kaempferia galamga phenolic glycoside of Quercetin glycosides 22
The eriodictyol glycosides 17 of 20 naringenin glycosides of anthocyanin 19.
Preparation method：
1) weight vine tea and the stoning red bayberry such as take to clean, mix, obtain mixture, it is standby；
2) the new arbutus and vine tea described in step 1) are soaked in the pure water of 5 times of gross weight and extracted, filtered, removed residual
Slag, concentration, by 1:1 ratio adds the mixture of alcohol and water, filters off except precipitation, supernatant cross silicagel column, using pure water to wash
De- liquid is eluted, and is collected efflux 60min liquid, concentration, is volatilized, obtain flavonoid glycoside composition.
The tablet of embodiment 9
Preparation method：
1) by the water of guar gum 2.5 times of amounts of addition, it is fully ground to amount of moisture and is less than 5% pastel, grinding is lower is added
Enter embodiment 4) prepared by composition, be well mixed, freeze-drying, be made inclusion compound；
2) inclusion compound is well mixed with 50% white bole and imidazolidine urea, mixture is made, granulation, it is white to add 50%
Clay, it is well mixed, tabletting, every weighs about 0.5g.
The tablet of embodiment 10
Preparation method：112 are prepared by the methods described of embodiment 7, every weighs about 0.8g.
The tablet of embodiment 11
Preparation method：150 are prepared by the methods described of embodiment 7, every weighs about 0.8g.
The pill of embodiment 12
Composition 30g prepared by embodiment 7
Auxiliary material：Xylitan monostearate 38g
Myristyl alcohol 5g
Preparation method：
1) xylitan monostearate and myristyl alcohol are placed in heat in water-bath and melted, fused mass is made, under stirring
The composition prepared by embodiment 7 is added, being sufficiently stirred makes composition be dispersed in fused mass, and fused solution is made；
2) fused solution is put in pill dripping machine；
3) dripping is carried out with 10 DEG C of atoleine, 100 pills is made, every weighs about 0.7g.
The capsule of embodiment 13
Preparation method：
1) composition is added in PLA acetic anhydride, grinding is uniform, and abrasive material is made；The pregel of 2/3 weight is formed sediment
Powder is 1 by volume:2 are added to the water, and the aqueous solution is made；Abrasive material and the aqueous solution are well mixed, in high speed shearing emulsification, system
Obtain colostrum；Colostrum is placed in high pressure homogenizer and emulsified, emulsion is made；By emulsion ultramicro grinding, it is 10 μm that particle size range, which is made,
Micro-capsule；
2) micro-capsule is well mixed with remaining pregelatinized starch, mixed powder is made；
3) hydroxypropyl methylcellulose is dissolved in absolute ethyl alcohol, adds mixed powder, be well mixed, softwood processed；
4) softwood is crossed into 24 mesh sieves, wet granular processed, wet granular be spray-dried, carry out whole grain, particle is made；
5)；Will be particles filled in capsule shells made from step 4), 100 capsules are made, every weighs about 0.3g.
Test stability and the antioxidation experiment of 1 flavonoid glycoside composition
1 test material
1.1 instruments and reagent：
AE-240 electronic analytical balances (plum Teller-Tuo Li Instrument Ltd.)
UV-2401 types spectrophotometer (Japanese Shimadzu)
Hydroxyl radical-scavenging ability determines kit, purchased from Jiang Lai bio tech ltd.
1.2 test group medicines：
Test group 1：Prepared flavonoid glycoside composition in embodiment 4；
Test group 2, prepared flavonoid glycoside composition in embodiment 6.
1.3 control group medicines：
Control group 1：The general flavone contained in red bayberry, medical grade, Zhejiang natural product chemistry Co., Ltd, lot number：
D20141226；
Control group 2：The general flavone contained in vine tea, medical grade, Zhejiang natural product chemistry Co., Ltd, lot number：
20140302。
The preparation of 1.4 prepare liquids：
Test group and control sample accurately are weighed, is each configured to the aqueous solution that concentration is 0.05mg/ml, it is standby；
The measure of 2 oxygen radical removing rates
Take test group 1, test group 2, control group 1 and each four parts of the aqueous solution of control group 2 respectively, 30 DEG C place 10min, 1h,
After 6h and 12h 1 is shown in Table with Hydroxyl radical-scavenging ability measure kit, the oxygen radical removing rate of determination sample, testing result.
The scavenging activated oxygen Activity determination result of table 1
The * * p compared with test group 1<0.01,ap<0.05,bP ＞ 0.05；The ##p compared with test group 2<0.01.
3. conclusion
Result of the test shows that flavonoid glycoside composition of the present invention has preferable scavenging activated oxygen to act on, and stably
Property is preferable, and effect is basicly stable constant after 12h.The flavone compound of control group also has preferable antioxidant radical activity,
But its stability is poor, the clearance rate of oxygen radical is less than 50% after 6h.
Test the hypoglycemic effect experiment of 2 flavonoid glycoside compositions
1 test material
1.1 experimental animal：SD mouse, male and female dual-purpose, 180-250g, Wuhan University animal testing center provide, conventional feed,
Credit number：SCXK (Hubei Province) 2008-0004.
1.2 medicine：
Test group 1：Prepared flavonoid glycoside composition in embodiment 4；
Test group 2, prepared flavonoid glycoside composition in embodiment 6.
Control group 1：The general flavone contained in red bayberry, medical grade, Zhejiang natural product chemistry Co., Ltd, lot number：
D20141226；
Control group 2：The general flavone contained in vine tea, medical grade, Zhejiang natural product chemistry Co., Ltd, lot number：
20140302。
Streptozotocin sigma products, lot number：20140506.
2 test methods
60 SD rats are randomly assigned, for 6 groups, every group 10,5 groups to be randomly selected, by by 50mg/kg disposable celiacs
Streptozotocin solution is injected, takes blood from rat tail vein after 72h, centrifuges serum, fasting blood-glucose is determined by kit method,
Blood glucose value >=16mmol/L, illustrate modeling successfully.By 5 groups of rats be randomly assigned for test group 1, test group 2, control group 1,
Control group 2 and model group, do not inject in addition streptozotocin solution for blank group.Gavage is given respectively daily for test group and control group
Medicine once, each 50mg/kg, blank group and model group gavage same volume distilled water, successive administration 15d.After last dose, every group
Rat gives yellow Jackets 40mg/kg, intraperitoneal injection of anesthesia, abdominal aortic blood, centrifuges serum, determines fasting blood
Sugar.
3. data processing
Statistical analysis is carried out using SPSS10.0 softwares.Measurement data is represented with (χ ± S), as a result carries out t inspections；Count
Data uses Chi-square Test.P<0.05 is significant difference, and result of the test is shown in Table 2.
Influence of the medicine of table 2 to blood glucose in diabetic rats
Compared with blank group@@p<0.01；Compared with model group&&p<0.01,ap<0.05；The * * p compared with test group 1<
0.05；Compared with test group 2##p<0.05。
4. conclusion
From experiment, for successive administration after 15 days, test group and control group mice fasting blood-glucose content have reduction, but try
Control group will be substantially better than by testing group therapeutic effect, i.e., flavonoid glycoside composition of the present invention, each component synergy, drop blood
Sugared effect is better than single plant Flavonoids.
Test therapeutic action of the 3 flavonoid glycoside compositions to Spontaneous Diabetic
1 test material
1.1 experimental animal：SD mouse, male and female dual-purpose, 180-250g, Wuhan University animal testing center provide, conventional feed,
Credit number：SCXK (Hubei Province) 2008-0004；Spontaneous Diabetic mouse, Nanjing model animal center provide.
1.2 medicine：
Test group 1：Prepared flavonoid glycoside composition in embodiment 4；
Test group 2：Prepared flavonoid glycoside composition in embodiment 6；
Control group 1：The general flavone contained in red bayberry, medical grade, Zhejiang natural product chemistry Co., Ltd, lot number：
D20141226；
Control group 2：The general flavone contained in vine tea, medical grade, Zhejiang natural product chemistry Co., Ltd, lot number：
20140302。
2 test methods
30 spontaneous diabetes B (OLETF) rats are randomly assigned as 5 groups, every group 6, respectively test group 1,
Test group 2, control group 1, control group 2 and model group, blank group select 6 healthy SD rats.Test group and control group are distinguished daily
Gastric infusion once, each 50mg/kg, blank group and model group gavage same volume distilled water, successive administration 30d.Then measure
Blood pressure, blood measurement blood glucose and blood fat, result of the test is taken to be shown in Table 3；Cored after execution, blood vessel, kidney, pathological study, experiment
As a result Fig. 1 is seen.
3. data processing
Statistical analysis is carried out using SPSS10.0 softwares.Measurement data is represented with (χ ± S), as a result carries out t inspections；Count
Data uses Chi-square Test.P<0.05 is significant difference.
Influence of the medicine of table 3 to Bb Wistar Rats With Spontaneous Diabetes blood pressure, blood glucose, blood fat
Compared with blank group@@p<0.01；Compared with model group&&p<0.01；ap<0.05；The * * p compared with test group 1<
0.01；Compared with test group 2##p<0.01。
4. conclusion
Results showed that flavonoid glycoside composition of the present invention can effectively reduce the blood of Bb Wistar Rats With Spontaneous Diabetes
Sugar, while mouse hypertension as caused by diabetes, hyperglycaemia and hyperlipidemia complication shape are reduced, significant effect, medicine feed 30 days,
Indices are close to normal value.And the single flavones less effective of control group.
Pathological study result is understood, diabetes rat vascular smooth muscle hyperplasia, causes vessel diameter narrow；Cardiac muscle
Cell arrangement is disorderly；The nephron is reduced, nephridial tissue atrophy.After flavonoid glycoside composition, vessel diameter substantially broadens, cardiac muscle
Cell and nephridial tissue tend to be normal, say that the flavonoid glycoside composition belonging to the present invention has good vascular protection effect, the heart
Flesh protective effect and renal protection.The single flavone compound of control group has certain protection to blood vessel, cardiac muscle and nephridial tissue
Effect, but effect is not so good as flavonoid glycoside composition.
Therefore, flavonoid glycoside composition of the present invention has preferably effect in terms for the treatment of diabetes and its complication
Fruit, and property is stable, can store, can patent medicine, there is more wide potential applicability in clinical practice, being one has innovative and use
The invention of value.
Claims (8)
1. a kind of flavonoid glycoside composition, it is characterised in that the composition is made up of the composition of following parts by weight：
Quercetin glycosides 0.01-20 kaempferia galamga phenolic glycoside 0.01-30 dihydromyricetin glycosides 0.01-20
Anthocyanin 0.01-20 naringenin glycosides 0.01-20 eriodictyol glycosides 0.01-20；
The flavonoid glycoside compound is using weight part ratio as 1:1 red bayberry and the mixture of vine tea are described made from raw material
The preparation method of flavonoid glycoside composition comprise the following steps：
1) take vine tea and stoning red bayberry to clean, mix, obtain mixture, it is standby；
2) mixture obtained by step 1) is added in the solvent of 4-6 times of gross weight and extracted, filtered, remove residue, concentration, by 1:
8-8:1 ratio adds the mixture of alcohol and water, filters off except precipitation, supernatant crosses silicagel column, using the solvent as eluent
Eluted, collect efflux 10-60min liquid, concentration, volatilize, obtain flavonoid glycoside composition.
2. flavonoid glycoside composition as claimed in claim 1, it is characterised in that the composition by following parts by weight composition
Composition：
Quercetin glycosides 1-20 kaempferia galamga phenolic glycoside 20-26 dihydromyricetin glycosides 0.5-20
Anthocyanin 14-20 naringenin glycosides 2-20 eriodictyol glycosides 15-20.
3. flavonoid glycoside composition as claimed in claim 1, it is characterised in that the composition by following parts by weight composition
Composition：
The dihydromyricetin glycosides 20 of 1 kaempferia galamga phenolic glycoside of Quercetin glycosides 25
The eriodictyol glycosides 20 of 14 naringenin glycosides of anthocyanin 20.
4. solid pharmaceutical preparation made of the flavonoid glycoside composition and auxiliary material as described in claim 1-3 is any, it is characterised in that institute
Stating solid pharmaceutical preparation includes tablet, capsule, powder or pill；The ratio of weight and number of the composition and auxiliary material is 1:1.5-3.
5. solid pharmaceutical preparation made of flavonoid glycoside composition as claimed in claim 4 and auxiliary material, it is characterised in that the solid
Preparation is tablet, and the auxiliary material includes guar gum, imidazolidine urea and white bole；The guar gum, imidazolidine urea and white bole
Ratio of weight and number is 8-10:1:10-12.
6. flavonoid glycoside composition as claimed in claim 1, it is characterised in that the solvent is 70%-95% ethanol, described
Method comprises the following steps：
1) take vine tea and stoning red bayberry to clean, mix, obtain mixture, it is standby；
2) mixture obtained by step 1) is added in the 70%-95% ethanol of 4-6 times of gross weight and extracted, filtered, remove residue,
Concentration, by 1:8 ratio adds the mixture of alcohol and water, filters off except precipitation, supernatant cross silicagel column, using 95% ethanol to wash
De- liquid is eluted, and is collected efflux 10-30min liquid, concentration, is volatilized, obtain flavonoid glycoside composition.
7. flavonoid glycoside composition as claimed in claim 6, it is characterised in that the solvent is pure water, and methods described includes
Following steps：
1) take vine tea and stoning red bayberry to clean, mix, obtain mixture, it is standby；
2) mixture obtained by step 1) is added in the pure water of 4-6 times of gross weight and extracted, filtered, remove residue, concentration, by 8:
1 ratio adds the mixture of alcohol and water, filters off except precipitation, supernatant are crossed silicagel column, eluted by eluent of pure water,
Efflux 10-60min liquid is collected, concentration, volatilizes, obtains flavonoid glycoside composition.
8. the flavonoid glycoside composition as described in claim 1-3 is any is preparing the medicine for treating diabetes and its complication
Application in thing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510392152.5A CN105816473B (en) | 2015-07-06 | 2015-07-06 | A kind of flavonoid glycoside composition and its preparation and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510392152.5A CN105816473B (en) | 2015-07-06 | 2015-07-06 | A kind of flavonoid glycoside composition and its preparation and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105816473A CN105816473A (en) | 2016-08-03 |
| CN105816473B true CN105816473B (en) | 2018-04-10 |
Family
ID=56514447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510392152.5A Active CN105816473B (en) | 2015-07-06 | 2015-07-06 | A kind of flavonoid glycoside composition and its preparation and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105816473B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008115723A1 (en) * | 2007-03-19 | 2008-09-25 | Atm Metabolics Lllp | Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid |
| US9943535B2 (en) * | 2012-12-06 | 2018-04-17 | Conopco, Inc. | Edible composition comprising resveratrol and flavonoid monoglucoside |
| CN104095868B (en) * | 2014-07-25 | 2016-06-01 | 烟台市华文欣欣医药科技有限公司 | A kind of pharmaceutical composition and pharmaceutical applications thereof improving sugar tolerance |
-
2015
- 2015-07-06 CN CN201510392152.5A patent/CN105816473B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105816473A (en) | 2016-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nagalingam | Drug delivery aspects of herbal medicines | |
| Amjad et al. | A novel strategy of nanotized herbal drugs and their delivery in the treatment of diabetes: Present status and future prospects | |
| CN107233442A (en) | It is a kind of that there is the composition and fingerprint for improving gout malaise symptoms | |
| CN106943372A (en) | A kind of auxiliary hyperglycemic soft capsule and its production technology | |
| Mukhtar et al. | Effect of aqueous extract of Cyamopsis tetragonoloba Linn. beans on blood glucose level in normal and alloxan-induced diabetic rats | |
| CN104666643B (en) | A kind of compound snow chrysanthemum product and its preparation method and application | |
| CN102716135B (en) | Lupenone prevents in preparation or treats the application in the product of diabetes | |
| CN102488725A (en) | Brain-soothing emulsion for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1329049C (en) | Blood sugar- and blood pressure-lowering medicine | |
| CN101278965A (en) | Soft capsule of humifuse spurge and preparing method thereof | |
| CN105816473B (en) | A kind of flavonoid glycoside composition and its preparation and preparation method | |
| CN100581552C (en) | Compound puerarin for treating cardiovascular and cerebrovascular disease | |
| CN100431562C (en) | Chinese traditional medicinal preparation containing red sange root and safflower for treating cardiovascular and cerebrovascular diseases and preparing process thereof | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| Ginting et al. | In Vivo study of Antidiabetic Activity from Ethanol Extract of Clitoria ternatea L. Flower | |
| CN107823207B (en) | A kind of combination of oral medication for treating atherosclerosis | |
| CN101278940A (en) | Medicament composition for curing diabetic cardiovascular pathological changes and method of preparing the same | |
| CN107998142B (en) | A kind of combination of oral medication for treating myocardial ischemia-reperfusion injury | |
| KR100447668B1 (en) | Method for preparing functional drink comprising dispersing pieces of jelly containing water-insoluble bioactive materials | |
| Mitra et al. | Anti Diabetic Plants of Sikkim & Darjeeling Himalayas (India) | |
| RU2442595C2 (en) | Herbal complex for treatment of oncological diseases and method for treatment of digestive tract diseases using the said complex | |
| KR0128493B1 (en) | Process for prepating jang won soft capsule | |
| CN107115424A (en) | Change acidic constitution and protect calcium and clearing heat and detoxicating Chinese medicine composition and preparation method | |
| Igwe et al. | Evaluation the Effect of Vernonia amygdalina. Del Leaves Ethanol Extract on Blood Sugar and its Synergism with Glibenclamide in Rats. | |
| CN107325071A (en) | A kind of preparation method and purposes of the Hickory Leaves pinostrobin with hypoglycemic effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231227 Address after: 430024, 5th Floor, Zone C, No. 6 Jiangwang Road, Economic Development Zone, Jianghan District, Wuhan City, Hubei Province Patentee after: WUHAN WORDNER UNITED PHARMACEUTICAL Co.,Ltd. Patentee after: WUHAN University Address before: No. 8 Jiangwang Road, Jianghan Economic Development Zone, Wuhan City, Hubei Province, 430023 Patentee before: WUHAN WORDNER UNITED PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |